MeiraGTx Holdings plc Ordinary Shares MGTX
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $25.00 (+92.3% upside)
Key Stats
- Today's Range
- $12.83 – $13.47
- 50-Day Range
- $11.28 – $15.31
- 52-Week Range
- $6.62 – $15.35
- Volume
- 495K shs
- Average Volume
- 715K shs
- Market Cap
- $1.27 billion
- P/E Ratio
- 14.94
- Dividend Yield
- —
Valuation
- P/E Ratio
- 14.94
- Price / Book
- 5.90
- Price / Sales
- 3.20
Short Interest
- Short Interest
- 0.33%
- Days to Cover
- 1.25
Financials (TTM)
- Revenue
- $397.50 million
- Net Income
- $78.93 million
- Net Margin
- 19.86%
- Return on Equity
- 36.58%
- Debt-to-Equity
- —
About MeiraGTx Holdings plc Ordinary Shares
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Related Stocks
Compare head-to-head: MGTX vs AMGN·MGTX vs MRNA·MGTX vs HALO·MGTX vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.